The past 48 hours "have been pretty emotional and overwhelming," Bluebird Bio Inc. CEO Nick Leschly told BioWorld, and he wasn't talking about navigating the street crowd at the 37th Annual J.P. Morgan (JPM) Healthcare Conference. Between meetings in San Francisco, Leschly had fielded dozens of calls from biopharma CEOs, payer representatives, key opinion leaders, patient advocacy organizations, government officials around the world – even employees and board members – reacting to the presentation at JPM where Leschly made the case for capped, at-risk, term-limited, installment-plan payments for potentially curative gene therapy and other one-time treatments. The response across stakeholders was uniformly heartening.